CTTH — CTT Pharmaceutical Holdings Share Price
Last trade - 00:00- $3.63m
- $3.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.42 | ||
| Price to Tang. Book | 4.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -226.31% | ||
| Return on Equity | -448.83% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CTT Pharmaceutical Holdings, Inc. is a development stage company. The Company is specialized in drug delivery systems technology within the pharmaceutical industry. The Company is focused is on fast dissolving drug delivery systems through the development of advanced oral delivery thin wafers. The Company plans to specialize in the development of oral drug delivery systems for pain management and treatment. Film strip encapsulated with the actives to help in pain reduction can include many combinations to help reduce pain and addiction and help patient safely. Oral Thin strips helps in pain management and inflammation indications, such as Arthritis. The Company has invented an ideal intra oral, fast-dissolving drug delivery system. This novel intraoral drug delivery system is its proprietary patented technology and is a thin, flexible and quick-dissolving film.
Directors
- William Birge PRE (58)
- Pankaj Modi CEO (65)
- Robert Allen CFO
- Dean Hanisch TRS (44)
- Allen Greenspoon DRC (60)
- Dana Buschmann IND
- Last Annual
- December 31st, 2014
- Last Interim
- September 30th, 2015
- Incorporated
- November 6th, 1996
- Public Since
- April 18th, 1997
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 48,342,381
- Address
- 3853 Northdale Blvd #268, TAMPA, 33624
- Web
- https://www.cttpharmaceuticals.com/
- Phone
- +1 8136060060
- Auditors
- MNP LLP
Upcoming Events for CTTH
Similar to CTTH
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 20:09 UTC, shares in CTT Pharmaceutical Holdings are trading at $0.07. This share price information is delayed by 15 minutes.
Shares in CTT Pharmaceutical Holdings last closed at $0.07 and the price had moved by +380.43% over the past 365 days. In terms of relative price strength the CTT Pharmaceutical Holdings share price has outperformed the S&P500 Index by +303.2% over the past year.
There is no consensus recommendation for this security.
CTT Pharmaceutical Holdings does not currently pay a dividend.
CTT Pharmaceutical Holdings does not currently pay a dividend.
CTT Pharmaceutical Holdings does not currently pay a dividend.
To buy shares in CTT Pharmaceutical Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.07, shares in CTT Pharmaceutical Holdings had a market capitalisation of $3.26m.
Here are the trading details for CTT Pharmaceutical Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CTTH
Based on an overall assessment of its quality, value and momentum CTT Pharmaceutical Holdings is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CTT Pharmaceutical Holdings. Over the past six months, its share price has outperformed the S&P500 Index by +177.84%.
As of the last closing price of $0.07, shares in CTT Pharmaceutical Holdings were trading +162.59% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CTT Pharmaceutical Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CTT Pharmaceutical Holdings' management team is headed by:
- William Birge - PRE
- Pankaj Modi - CEO
- Robert Allen - CFO
- Dean Hanisch - TRS
- Allen Greenspoon - DRC
- Dana Buschmann - IND